alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
##### 



CERTIFICATE OF
PRINCIPAL EXECUTIVE OFFICER
OF
AMERICAN CELLULAR CORPORATION
  a.
    
    fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; andb.
    
    the information contained in the Report fairly presents, in all material respects, the financial condition of
the Company at September 30, 2006, and the results of the
Companys operations for the period ended September
30, 2006.
 November 9, 2006
    /s/ STEVEN P. DUSSEKSteven P. DussekChief Executive Officer
and principal executive officer
**************************

* MONOGRAPH NO: 1A1A

**************************

ITEM: Country Captain Chicken (CAP) (PRIMARY)

NSN: 8940-01-484-0502 ITEM SPECIFICATION: PCR-C-043 Can

 8940-01-484-0503 PCR-C-044 Poly

CHARACTERISTICS OF ITEM:

APPEARANCE: light tan, whole muscle, cooked chicken breast in low 

viscosity red to orange tomato-based sauce containing slivered almonds, 

mushrooms, green pepper pieces, onion, currants, and specks of spice

ODOR: slight tomato; curry; cooked chicken

FLAVOR: slightly sweet tomato; cooked chicken; onion; cooked nuts; curry

TEXTURE: slightly moist and tender chicken; smooth sauce; soft vegetables

ESTIMATED SHELF-LIFE AT: 80 DEGREES F: 36 mo

 100 DEGREES F: 6 mo

POSSIBLE DETERIORATIVE CHANGES:

Appearance: darkened chicken and sauce; broken up chicken; weeping of 

sauce

Odor: old; scorched; rancid; loss of curry

Flavor: overcooked chicken; metallic; sour; bland; loss of curry flavor

Texture: dry, stringy chicken; separated or thickened sauce

UNIQUE EXAMINATION/TEST PROCEDURES: None
No. 11-6899.

#### Eli Esmael, Petitioner v. United Kingdom Secret Intelligence Service, et al.

565 U.S. 1119, 132 S. Ct. 1012,

181 L. Ed. 2d 748,

2012 U.S. LEXIS 364.

January 9, 2012.

Petition for writ of certiorari to the Court of Appeal of California, Second Appellate District, denied.
Exhibit 10.20


First Amendment


Employment Agreement


 


 


THIS AMENDMENT, made and entered
into as of the 17th day of January, 2012, by and between Polonia Bancorp, a federally-chartered corporation (the “Company”)
and Anthony J. Szuszczewicz, an employee of the Company (the “Executive”).


 


WHEREAS, the Executive and the Company
entered into an amended and restated employment agreement, dated as of December 16, 2008 (the “Agreement”);
and


 


WHEREAS, the Executive and the Company
desire to amend the Agreement to make certain changes to the Company’s potential severance obligations under the Agreement;
and


 


WHEREAS, Section 21 of the Agreement
provides that the parties may amend the Agreement from time to time.


 


ACCORDINGLY, the Agreement is hereby
amended, effective as of January 17, 2012, as follows:


 


 


Section 11(f)(ii) of the Agreement is deleted in its entirety
and replaced with the following new Section 11(f)(ii):


 


“Subject to Section 12 of this Agreement,
in the event of termination under this Section 11(f), Executive will receive an amount equal to his base salary and the value of
employer contributions to benefit plans in which Executive participated upon termination that would have been paid or provided
to Executive for a period of one year from the date of his termination of employment, paid in one lump sum within ten (10) calendar
days of his termination. Executive will also continue to participate in any benefit plans of the Company that provide medical,
dental and life insurance coverage for a period of one year from the date of his termination of employment, under terms and conditions
no less favorable than the most favorable terms and conditions provided to senior executives of the Company during the same period.
If the Company cannot provide such coverage because Executive is no longer an employee, the Company will provide Executive with
comparable coverage on an individual policy basis or the cash equivalent.”


 




[signature page follows]





 






    	 



    	 	



    
 


IN WITNESS WHEREOF, the parties hereto each acknowledge
that each has carefully read this amendment to the Agreement and executed the original on the date indicated.


 


 





	 	 	POLONIA BANCORP
	 	 	 
	 	 	 
	/s/ Elaine L. Milione	 	/s/ Paul D. Rutkowski
	Witness	 	For the Company
	 	 	 
	January 17, 2012	 	 
	Date	 	 
	 	 	 
	 	 	 
	 	 	EXECUTIVE
	 	 	 
	 	 	 
	/s/ Lynn Lucia	 	/s/ Anthony J. Szuszczewicz
	Witness	 	Anthony J. Szuszczewicz
	 	 	 
	January 17, 2012	 	 
	Date
No. 11-7837.

#### Elisha Joshua Nunnery, Petitioner v. United States.

565 U.S. 1171, 132 S. Ct. 1126,

181 L. Ed. 2d 1004,

2012 U.S. LEXIS 640.

January 17, 2012.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.

Same case below, 441 Fed. Appx. 240.
Letter from the General Partner extending Mgmt Agreement with Graham Capital



 Exhibit 10.9(a) 
 June 1, 2011 
 Graham Capital Management, L.P. 

Rock Ledge Financial Center 
 40 Highland Avenue

 Rowayton, CT 06853 
 Attention:
Mr. Paul Sedlack 
 Re: Management Agreement Renewals  
 Dear Mr. Sedlack: 
 We are writing with respect to your management agreements concerning the
commodity pools to which reference is made below (the “Management Agreements”). We are extending the term of the Management Agreements through June 30, 2012 and all other provisions of the Management Agreements will remain unchanged.

  

	 	•	 	 Diversified 2000 Futures Fund L.P. 


  

	 	•	 	 Fairfield Futures Fund L.P. 


  

	 	•	 	 Diversified Multi-Advisor Futures Fund L.P. 


  

	 	•	 	 Diversified Multi-Advisor Futures Fund L.P. II 



 

	 	•	 	 Tactical Diversified Futures Fund L.P. 


  

	 	•	 	 Fairfield Futures Fund L.P. II 


  

	 	•	 	 CMF Graham Capital Master Fund L.P. 


 Please acknowledge receipt of this modification by signing one copy of this letter and returning it to the attention of Ms. Jennifer Magro at the address above or fax to 212-296-6868. If you have any
questions I can be reached at 212-296-1302. 
 Very truly yours, 

 

					
	 CERES MANAGED FUTURES LLC
	 	
			
	By:	 	 /s/ Jennifer Magro
	 	
		 	Jennifer Magro	 	
		 	Chief Financial Officer & Director	 	
		
	GRAHAM CAPITAL MANAGEMENT, L.P.	 	
			
	By:	 	 /s/ Paul Sedlack
	 	
		 	Print Name: Paul Sedlack	 	

 JM/sr
1

Centers for Disease Control and Prevention

National Center for Immunization and Respiratory Diseases

Maternal/Pediatric Respiratory Syncytial Virus (RSV) 

Work Group

Sarah S. Long, MD

Chair, Maternal/Pediatric RSV Work Group 

ACIP General Meeting

June 22, 2023
2

Work group members (External)

ACIP Members

Sarah Long (chair)

Pablo Sanchez

Oliver Brooks

Camille Kotton

Ex Officio Members

Rachel Zhang (FDA-CBER)

Nicholas Geagan (FDA-CBER)

Judy Beeler (FDA-CBER)

Yodit Belew (FDA-CDER)

Prabha Viswanathan (FDA-CDER)

Sonnie Kim (NIH-NIAID)

April Killikelly (Public Health Agency of Canada)

Winnie Siu (Public Health Agency of Canada)

Valerie Marshall (OIDP/OASH)

Jessica Lee (CMS/CMCS)

Terry Dalle-Tezze (HRSA)

Lucia Lee (FDA-CBER)

Consultants

Cody Meissner (Dartmouth Geisel School of Medicine)

Helen Chu (University of Washington)

Natasha Halasa (Vanderbilt University)

Denise Jamieson (Emory University School of Medicine)

Daniel Feikin (World Health Organization)

Carol Baker (University of Texas Health Science Center)

Kevin Ault (Western Michigan University)

Liaisons

James McAuley (IDSA)

Patsy Stinchfield (NFID)

Brenna L. Hughes (ACOG)

Nicole Chaisson (AAFP)

Sean O’Leary (AAP)

Jennifer Schuster (PIDS)

Molly Howell (AIM)

GRADE/EtR consultants

Doug Campos-Outcalt

Rebecca Morgan
3

Work group members (CDC)

Lauren Roper

Amber Winn

Chris Taylor

Tami Skoff

Angie Campbell

Michael Melgar

Amanda Payne

Nicole Dowling

Noelle Molinari

Claire Midgley

Fiona Havers

Pragna Patel

Andrea Sharma

Amadea Britton

Ruth Link-Gelles

Danielle Moulia

Megan Wallace

Monica Godfrey

CDC ACIP Staff

Melinda Wharton

Stephanie Thomas

Jessica MacNeil

Karen Broder

Naomi Tepper

Hannah Rosenblum

Heidi Moline

Derrell Powers

Raigan Wheeler

Sally Ezra

Elizabeth Greene

CDC

Katherine Fleming-Dutra (co-lead)

Jefferson Jones (co-lead)

Meredith McMorrow

Mila Prill

Natalie Thornburg

Aron Hall

Ismael Ortega-Sanchez

Melissa Coughlin

Jamison Pike

A. Patricia Wodi

Neil Murthy

Christine Olson

Anne Hause

Andrew Leidner

David Shay
4

▪ Epidemiology and burden of RSV in infants

▪ Virology and immunology of RSV

▪ Safety and efficacy of nirsevimab

▪ Cost effectiveness analysis for nirsevimab – CDC model

▪ Cost effectiveness analysis for nirsevimab – Comparison to manufacturer model

▪ Evidence to Recommendations framework for nirsevimab

▪ Clinical considerations for nirsevimab

▪ Safety and Efficacy of RSV Bivalent PreF Maternal Vaccine

Previous maternal/pediatric RSV ACIP presentations
5

Agenda: Thursday June 22, 2023

▪ Economic Analysis of RSVpreF in 

Pediatric Populations

▪ Evidence to Recommendations 

Framework for Pfizer Maternal RSVpreF

Vaccine

▪ Economics of combined use of Pfizer 

maternal RSVpreF vaccine and 

nirsevimab

▪ Clinical considerations for 

RSVpreF maternal vaccine and 

nirsevimab

Dr. David Hutton (University of 

Michigan)

Dr. Katherine Fleming-Dutra (CDC)

Dr. David Hutton (University of 

Michigan)

Dr. Jefferson Jones (CDC)
6
[Federal Register Volume 63, Number 145 (Wednesday, July 29, 1998)]
[Notices]
[Page 40541]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-20260]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE


Notice of Lodging of Consent Decree Pursuant to the Comprehensive 
Environmental Response, Compensation and Liability Act

    In accordance with Departmental policy and consistent with 28 
C.F.R. 50.7 and Section 122 of CERCLA, 42 U.S.C. 9622, notice is hereby 
given that on July 13, 1998, a proposed Consent Decree in United States 
v. White Consolidated Industries, Inc. and the Town of Franklin, 
Wisconsin., Civil Action No. 96-C-458, was lodged with the United 
States District Court for the Eastern District of Wisconsin. This 
consent decree represents a settlement of claims brought by the United 
States, pursuant to the Comprehensive Environmental Response, 
Compensation and Liability Act, 42 U.S.C. 9601 et seq., against White 
Consolidated Industries and the Town of Franklin, Wisconsin for 
reimbursement of response costs incurred at the Lemberger Flyash 
Superfund Site (``Site'') located in Manitowac County, Wisconsin.
    Under this settlement with the United States, White Consolidated 
Industries, Inc. will pay $600,000 and the Town of Franklin, Wisconsin 
will pay $120,000 in reimbursement of response costs incurred by the 
United States at the Site.
    The Department of Justice will receive for a period of thirty (30) 
days from the date of this publication comments relating to the 
proposed Consent Decree. Comments should be addressed to the Assistant 
Attorney General of the Environment and Natural Resources Division, 
Department of Justice, Washington, D.C. 20530, and should refer to 
United States v. White Consolidated Industries, Inc. and the Town of 
Franklin, Wisconsin, D.J. Ref. 90-11-2-712C.
    The proposed Consent Decree may be examined at the Office of the 
United States Attorney, Eastern District of Wisconsin, 330 Federal 
Building, 517 East Wisconsin Avenue, Milwaukee, Wisconsin, at the 
Region 5 Office of the Environmental Protection Agency, 77 West Jackson 
Street, Chicago, Illinois 60604-3590, and at the Consent Decree 
Library, 1120 G Street, N.W., 4th Floor, Washington, D.C. 20005, (202) 
624-0892. A copy of the proposed Consent Decree may be obtained in 
person or by mail from the Consent Decree Library, 1120 G Street, N.W., 
4th Floor, Washington, D.C. 20005. In requesting a copy, please enclose 
a check in the amount of $5.00 (.25 cents per page reproduction cost) 
payable to the Consent Decree Library.
Joel M. Gross,
Chief, Environmental Enforcement Section, Environment and Natural 
Resources Division.
[FR Doc. 98-20260 Filed 7-28-98; 8:45 am]
BILLING CODE 4410-15-M
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT
No. 97-7328
UNITED STATES OF AMERICA, Plaintiff - Appellee, versus CHARLES W. BAXTER, Defendant - Appellant. Appeal from the United States District Court for the District of Maryland, at Baltimore. William M. Nickerson, District Judge. (CR-93-122-WN, CA-97-262-WMN) Submitted: March 3, 1998 Decided: June 2, 1998 Before MURNAGHAN, ERVIN, and WILKINS, Circuit Judges. Dismissed by unpublished per curiam opinion. Charles W. Baxter, Appellant Pro Se. Lynne Ann Battaglia, United States Attorney, Baltimore, Maryland, for Appellee. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM: Appellant Charles W. Baxter seeks to appeal the district court's order denying his motion filed under 28 U.S.C.A. § 2255(West 1994 & Supp. 1997). We have reviewed the record and the district court's opinion and find no reversible error. Accordingly, wedeny a certificate of appealability and dismiss the appeal substantially on the reasoning of the district court. See United States v. Baxter , Nos. CR-93-122-WN; CA-97-262-WMN (D. Md. Aug. 20, 1997). We find Baxter's claim of ineffective assistance of counsel regarding the allegedly duplicitous indictment meritless because he failed to establish that he was prejudiced by counsel's performance. See Strickland v. Washington, 466 U.S. 668, 687-88, 694 (1984). We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

DISMISSED
No. 11-6826.

#### Thomas Pratt, Petitioner v. Board of Pharmacy, et al.

565 U.S. 1069, 132 S. Ct. 782,

181 L. Ed. 2d 500,

2011 U.S. LEXIS 8639.

November 28, 2011.

Petition for writ of certiorari to the Court of Appeal of California, Third Appellate District, denied.
<page>

EXHIBIT 32.01

CERTIFICATION OF PRESIDENT PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




In connection with the Quarterly Report of Morgan Stanley Charter
Graham L.P. (the "Partnership") on Form 10-Q for the quarter ended
June 30, 2009, as filed with the Securities and Exchange
Commission on the date hereof (the "Report"), I, Walter Davis,
President of Demeter Management LLC, the general partner of the
Partnership, certify, pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that, to the best of my knowledge:
(1)	The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents,
in all material respects, the financial condition and
results of operations of the Partnership.









By:   /s/ Walter Davis

Name:		Walter Davis
Title:	President of Demeter Management LLC,
			the general partner of the Partnership

Date:		August 12, 2009
CERTIFICATION OF CEO PURSUANT TO 18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002








I, Don Gayhardt, Chief Executive Officer of CURO Group Holdings Corp. (the “Company”), hereby certify pursuant to Section 1350 of chapter 63 of title 18 of the United States Code, and Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: (1) the annual report on Form 10-K of the Company to which this Exhibit is attached (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.








_ /s/ Don Gayhardt _____________


Don Gayhardt


Chief Executive Officer


March 13, 2018
# C_2016366EN.01000801.xml

| 5.10.2016 | EN | Official Journal of the European Union | C 366/8 |
| --- | --- | --- | --- |

5.10.2016

EN

Official Journal of the European Union

C 366/8

---

Special Report No 24/2016

‘More efforts needed to raise awareness of and enforce compliance with State aid rules in cohesion policy’

(2016/C 366/07)

The European Court of Auditors hereby informs you that Special Report No 24/2016 ‘More efforts needed to raise awareness of and enforce compliance with State aid rules in cohesion policy’ has just been published.

The report can be accessed for consultation or downloading on the European Court of Auditors' website: http://eca.europa.eu or on EU Bookshop: https://bookshop.europa.eu

---
Date: 5 December 2023 **********************

NSN: 8920-01-711-1424 (BCO) * MONOGRAPH 5A13

 *********************

Item: Blueberries and cream oatmeal

Document: PCR-O-007, Oatmeal, Packaged in a Polymeric Tray, Shelf Stable

Approximate Caloric Value Per Serving: 190 Component Classification: Secondary

Estimated Shelf Life: 36 months at 80°F

Item Characteristics

Appearance:

Oatmeal: Cooked whole oats and groats, tan to light brown color, creamy, and may 

have a purple color from the cooked blueberries.

Blueberries: Dark purple color.

Odor: Cooked oatmeal, moderate sweet blueberry, and slight cooked cream.

Flavor: Cooked oatmeal, moderate sweet blueberry, and slight cooked cream.

Texture: Oatmeal: Moderately thick, slightly soft to slightly firm; not pasty.

Blueberries: Soft to slightly firm.

Possible Deteriorative Changes 

Appearance: Darkened oats, scorched blueberries.

Odor: Sour dairy, oxidized, fermented blueberry.

Flavor: Burnt, oxidized, off-dairy, fermented blueberry.

Texture: Pasty, very thick.

Unique Examination/Test Procedures

N/A

Special Notes

N/A
No. 11-7591.

#### Tywon Knight, Petitioner v. Yolande Johnson.

565 U.S. 1167, 132 S. Ct. 1116,

181 L. Ed. 2d 997,

2012 U.S. LEXIS 826.

January 17, 2012.

Petition for writ of certiorari to the United States Court of Appeals for the Seventh Circuit denied.
No. 11-440.

#### Schupak Group, Incorporated, Petitioner v. Travelers Casualty and Surety Company of America.

565 U.S. 1093, 132 S. Ct. 849,

181 L. Ed. 2d 549,

2011 U.S. LEXIS 8844.

December 12, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Second Circuit denied.

Same case below, 425 Fed. Appx. 23.
Date: 23 June 2023 *********************

NSN: 8940-01-711-1632 (MAC) *MONOGRAPH 1A1O

 *********************

Item: Macaroni and cheese, cooked, dehydrated

Document: PCR-M-019, Macaroni and Cheese, Cooked, Dehydrated, Packaged in a Boil-In-Bag 

(BIB)

Approximate Caloric Value Per Serving: 235 Component Classification: Primary

Estimated Shelf Life: 36 months at 80°F

Item Characteristics

Appearance:

Dehydrated product: Cooked elbow macaroni in a cheddar cheese sauce powder.

Elbow macaroni: Enriched, elbow shaped, off-white to light tan color. May have a 

yellow-orange color from the sauce powder.

Cheddar cheese sauce: Light to medium yellow-orange color, free-flowing powder. 

May contain some clumps.

Rehydrated product: Elbow macaroni in a cheddar cheese sauce.

Elbow macaroni: Discernible, off-white to light tan color. May have a yellow-orange 

color from the sauce.

Cheddar cheese sauce: Light to medium yellow-orange color, slightly smooth and 

moderately thick.

Odor: Dehydrated product: Cooked macaroni and cooked dairy.

Rehydrated product: Cooked macaroni and mild cheddar cheese.

Flavor: Rehydrated product: Cooked macaroni and mild cheddar cheese.

Texture:

Dehydrated product: No wet or soft spots indicating incomplete dehydration.

Rehydrated product: Elbow macaroni slightly soft to slightly firm.

Cheddar cheese sauce: Creamy and moderately thick.

Possible Deteriorative Changes 

Appearance: Dehydrated and rehydrated product: Excessive darkening or loss of color of sauce.

Odor: Dehydrated product: Burnt, sour macaroni and dairy.

Rehydrated product: Burnt, sour, oxidized macaroni and dairy.

Flavor: Dehydrated product: Burnt, sour macaroni and dairy.

Rehydrated product: Burnt, sour, oxidized macaroni and dairy.

Texture:

Dehydrated product: Very hard clumps of cheese sauce.

Rehydrated product: Elbow macaroni hard, not rehydrated.

Cheddar cheese sauce: Separated, clumpy.

Unique Examination/Test Procedures: N/A

Special Notes: N/A
Toxicity of rotenone to some potential predators on

marine fish larvae — An experimental study

Tore Næssa, Kjell E. Naasaand Ole B. Samuelsenb

a

Institute of Marine Research, Austevoll Aquaculture Research Station, N-5392 Storebø, Norway

bDepartment of Pharmacology and Toxicology, University of Bergen, Armauer Hansens House,

N-5021 Bergen, Norway

Received 28 September 1990;

accepted 17 February 1991.

Available online 1 October 2003.

Abstract

Toxicity of rotenone to some potential predators on marine fish larvae was tested experimentally.

Degradation of rotenone in seawater was 0·57% h−1at 50 lux and 10°C. The content of active

rotenone in the commercial solution was, on average, 79% of the expected value, probably

caused by age degradation of the product.

Fifty per cent mortality of the gobid Gobiusculus flavescens Fabricius occurred after 36, 16 and 5

h in 0·10, 0·25 and 0·50 ppm rotenone solutions, respectively. Fifty per cent mortality of the

mysid Praunus flexuosus(O. F. Müller) occurred after 27 h in 5·0 ppm solution. Of the tested

species, the carid shrimp Leander squillaL. had the highest tolerance to rotenone, and 10 ppm

was necessary to kill all specimens within 48 h. Fifty per cent mortality was registered within 19 h

at 10 ppm. The results are primarily compared with studies on limnetic species due to lack of data

on marine organisms.
[Federal Register Volume 74, Number 38 (Friday, February 27, 2009)]
[Notices]
[Page 8963]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-4210]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP): Assessing the Accuracy of Self-Report of HIV 
Testing Behavior, Program Announcement Number (PA) 09-002

    Correction: This notice was published in the Federal Register on 
February 10, 2009, Volume 74, Number 26, Page 6634. The place and time 
should read as follows:
    Time and Date: 12 p.m.-3 p.m., March 20, 2009 (Closed).
    Place: Teleconference.
    Status: The meeting will be closed to the public in accordance with 
provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and 
the Determination of the Director, Management Analysis and Services 
Office, CDC, pursuant to Public Law 92-463.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both CDC and the Agency for Toxic Substances and Disease Registry.

    Dated: February 13, 2009.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. E9-4210 Filed 2-26-09; 8:45 am]
BILLING CODE 4163-18-P